US FDA's process for reviewing test-waiver applications under the Clinical Laboratory Improvement Amendments (CLIA) is set to undergo enhancements based on a draft user-fee reauthorization agreement.
In the deal that was inked last month, the agency says it will establish a centralized management group for CLIA waiver review, and also implement updated performance measures and make...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?